Источники:

1. Ballantyne CM, et al. Efficacy and safety of bempedoic acid added to ezetimibe in statin-intolerant patients. Atherosclerosis. 2018;277:195-203. https://www.atherosclerosis-journal.com/article/S0021-9150(18)30309-5/fulltext
2. Collins R., et al. Interpretation of the evidence for the efficacy and safety of statin therapy; The Lancet. - 2016. - T. 388.-N; 10059.-C. 2532-2561
3. Francesco Natale F., Molinari R. et al. Bempedoic Acid and Statins in Lipid-Lowering Strategy: Which Came First, the Egg or the Chicken? Future Pharmacol. 2023, 3(2), 392-406; https://doi.org/10.3390/futurepharmacol3020024
4. Goldberg AC, et al. Effect of Bempedoic Acid vs Placebo Added to Maximally Tolerated Statin Therapy (CLEAR Wisdom). JAMA. 2019;322(18):1780-1788. https://jamanetwork.com/journals/jama/fullarticle/2754814
5. Haller MJ, Stein JM, Shuster JJ, et al. Pediatric Atorvastatin in Diabetes Trial (PADIT): A Pilot Study to Determine the Effect of Atorvastatin on Arterial Stiffness and Endothelial Function in Children with Type 1 Diabetes Mellitus. J Pediatric Endocrinol Metabol 2009; 22: 65-8.
6. Jones PH, et al. Comparison of the efficacy and safety of rosuvastatin versus atorvastatin, simvastatin, and pravastatin across doses (STELLAR Trial). Am J Cardiol. 2003;92(2):152-160. https://www.ajconline.org/article/S0002-9149(03)00530-7/fulltext
7. Ray KK, et al. Safety and Efficacy of Bempedoic Acid to Reduce LDL Cholesterol (CLEAR Harmony). N Engl J Med. 2019;380(11):1022-1032. https://www.nejm.org/doi/full/10.1056/NEJMoa1803917
8. Клинические рекомендации РФ «Диагностика и коррекция нарушений липидного обмена» (2023). https://cr.minzdrav.gov.ru/schema/752_1
9. Инструкция по медицинскому применению препарата Липлесс Плюс.